Bronchopulmonary Dysplasia Clinical Trial
Official title:
Sustained Inflations to Achieve Lung Aeration at Birth - a Randomized Control Trial
To determine if respiratory support at birth guided by RFM decreases BPD.
Despite recent advances in perinatal-neonatal care, there is an increasing trend of
bronchopulmonary dysplasia (BPD) among survivors of prematurity1. Most infants developing
BPD are born prematurely, and 75% of affected babies weigh less than 1000g at birth2. The
risk of developing BPD increases with decreasing birth weight with reported incidence as
high as 85% in neonates weighing between 500g and 699g, but only 5% in infants with birth
weights over 1500g2. Alberta has the highest rate (10%) of delivering premature infants in
Canada. In Edmonton approximately 200 premature infants <1250 g birth weight are born
annually and up to 50% will develop BPD. This puts a heavy burden on health resources since
these infants require frequent hospital re-admission in the first two years after birth and,
even as adolescents have persistent respiratory symptoms.
Hypothesis Preterm infants <33 weeks gestation requiring breathing support at birth, the
delivery of SIs (SI group) before mask ventilation compared to standard mask ventilation
(IPPV group) will reduce the incidence of BPD.
Aim To determine if respiratory support at birth with initial sustained inflation compared
to IPPV decreases BPD.
Study population Entry criteria Infants <33 weeks gestation born in the Royal Alexandra
Hospital who require respiratory support for resuscitation in the delivery room.
Exclusion criteria Infants will be excluded if they have a congenital abnormality or
condition that might have an adverse effect on breathing or ventilation, e.g. congenital
pulmonary or airway anomalies, congenital diaphragmatic hernia, or congenital heart disease
requiring intervention in neonatal period. Infants will also be excluded if their parents
refuse to give consent to this study.
Description of interventions "SI group" Infants randomized into the "SI group" will receive
two initial sustained inflations before PPV or CPAP.
"IPPV group" Infants randomized into the "IPPV group" will receive mask IPPV with an initial
PIP of 20 cmH2O and PEEP of 5 cm H2O, and a ventilation rate of 40-60 inflations/min until
spontaneously breathing, at which time CPAP will be provided.
"Failed SI or IPPV" Babies who fail to improve or remain apneic, bradycardic or hypoxemic
despite two SIs and/or 30 seconds of effective IPPV require an alternative airway. Unit
policy also dictates elective intubation and instillation of surfactant if, despite CPAP, a
preterm infant continues to have increased work of breathing or requires a sustained
inspiratory oxygen concentration over 40%.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04506619 -
Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants
|
||
Completed |
NCT04936477 -
Ventilation-perfusion (V/Q) Ratio and Alveolar Surface Area in Preterm Infants
|
N/A | |
Recruiting |
NCT05285345 -
Implementation of a Consensus-Based Discharge Protocol for Preterm Infants With Lung Disease
|
||
Completed |
NCT03649932 -
Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing
|
Phase 1 | |
Terminated |
NCT02524249 -
Early Versus Late Caffeine for ELBW Newborns
|
N/A | |
Completed |
NCT02249143 -
Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants
|
N/A | |
Active, not recruiting |
NCT01632475 -
Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia
|
||
Completed |
NCT01460576 -
Improving Prematurity-Related Respiratory Outcomes at Vanderbilt
|
N/A | |
Completed |
NCT00419588 -
Growth of Airways and Lung Tissues in Premature and Healthy Infants
|
||
Unknown status |
NCT00254176 -
Cysteine Supplementation in Critically Ill Neonates
|
Phase 2/Phase 3 | |
Completed |
NCT00319956 -
Trial II of Lung Protection With Azithromycin in the Preterm Infant
|
Phase 2 | |
Completed |
NCT00208039 -
Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates
|
N/A | |
Completed |
NCT00006401 -
Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants
|
Phase 3 | |
Terminated |
NCT05030012 -
Maintaining Optimal HVNI Delivery Using Automatic Titration of Oxygen in Preterm Infants
|
N/A | |
Completed |
NCT00006058 -
Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns
|
N/A | |
Completed |
NCT00005376 -
Premature Birth and Its Sequelae in Women
|
N/A | |
Completed |
NCT00011362 -
Dexamethasone Therapy in VLBW Infants at Risk of CLD
|
Phase 3 | |
Completed |
NCT00004805 -
Study of the Effect of Four Methods of Cardiopulmonary Resuscitation Instruction on Psychosocial Response of Parents With Infants at Risk of Sudden Death
|
N/A | |
Completed |
NCT05152316 -
The Baby Lung Study
|
||
Recruiting |
NCT04821453 -
NAVA vs. CMV Crossover in Severe BPD
|
N/A |